CytoVale is a biotechnology research company that uses early detection strategies for auto-immune diseases. The company has a mission of using diagnostic interventions to create faster, easier-to-implement medical treatment for patients. Other features of CytoVale are microfluidics and biophysical machine learning. CytoVale was founded by Ajay Shah and Dino Di Carlo in 2013 and is headquartered in San Francisco, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/10/2024 | Series D | $101MM | $xx.xx | $333.35MM | Alumni Ventures, Breakout Ventures, Cpp Investments, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital | |
Price per Share
$xx.xx
Shares Outstanding
36,422,641
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Breakout Ventures, Cpp Investments, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
|
||||||
11/15/2023 | Series C-3 | $10.24MM | $xx.xx | $188.41MM | Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital | |
Price per Share
$xx.xx
Shares Outstanding
6,874,563
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
|
||||||
11/15/2023 | Series C-4 | $178,987.00 | $xx.xx | $188.41MM | Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital | |
Price per Share
$xx.xx
Shares Outstanding
104,117
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
|
||||||
11/15/2023 | Series C-2 | $18.7MM | $xx.xx | $188.41MM | Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital | |
Price per Share
$xx.xx
Shares Outstanding
9,600,482
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
|
||||||
11/15/2023 | Series C-1 | $54.87MM | $xx.xx | $188.41MM | Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital | |
Price per Share
$xx.xx
Shares Outstanding
23,940,484
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Global Health Investment Corporation, Norwest Venture Partners, Sands Capital
|
||||||
10/30/2019 | Series B | $15MM | $xx.xx | $47.02MM | Blackhorn Ventures, Breakout Ventures, Western Technology Investment | |
Price per Share
$xx.xx
Shares Outstanding
5,614,823
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Blackhorn Ventures, Breakout Ventures, Western Technology Investment
|
||||||
06/10/2014 | Series A | $4.3MM | $xx.xx | $10.75MM | Dolby Family Ventures | |
Price per Share
$xx.xx
Shares Outstanding
3,185,185
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Dolby Family Ventures
|